CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Dr Lee on the Real-World Safety Profile of Axi-Cel in R/R LBCL

February 18th 2025

Dasom (Caroline) Lee, MD, details the safety results of second-line axicabtagene ciloleucel in real-world patients with relapsed/refractory LBCL.

Five Under 5: Top Oncology Videos for the Week of 2/9

February 16th 2025

The top 5 videos of the week cover insights in plexiform neurofibromas, melanoma, myeloma, leukemia, and LBCL.

Cilta-Cel Provides Deep MRD Negativity in Lenalidomide-Refractory Multiple Myeloma

February 15th 2025

Cilta-cel led to rapid and deep MRD negativity in patients with lenalidomide-refractory multiple myeloma.

Dr Spencer on the Rationale of Evaluating a Novel CAR T-Cell Product in Pancreatic Cancer

February 14th 2025

Kristen Spencer, DO, details the rationale of the phase 1/2 EVEREST-2 trial evaluating the novel CAR T product A2B694 in pancreatic cancer.

FDA Awards RMAT Designation to NXC-201 for Relapsed/Refractory AL Amyloidosis

February 13th 2025

The designation underscores the potential of the CAR T-cell therapy NXC-201 to serve as a new option in relapsed/refractory AL amyloidosis.

Dr Faries on Emerging CAR T-Cell and TCR Cell Therapies in Melanoma

February 11th 2025

Mark Faries, MD, discusses how CAR T-cell and TCR cell therapies compare with TIL approaches in melanoma.

Hematologic Oncology Field Sees Almost 20 FDA Approvals in 2024

February 11th 2025

The movement of CAR T-cell therapy to earlier lines of therapy was among many notable advancements greenlit by the FDA in the hematologic space in 2024.

Liso-Cel Generates Responses in R/R Marginal Zone Lymphoma

February 10th 2025

Lisocabtagene maraleucel elicited a statistically significant overall response rate in adult patients with relapsed/refractory MZL.

Five Under 5: Top Oncology Videos for the Week of 2/2

February 9th 2025

The top 5 videos of the week cover insights in lung cancer, multiple myeloma, breast cancer, and follicular lymphoma.

Axi-Cel Shows Durable Responses, May Have Curative Potential in R/R Indolent Non-Hodgkin Lymphoma

February 4th 2025

Sattava S. Neelapu, MD, discusses updated data from the 5-year follow-up analysis evaluating axi-cel in relapsed/refractory indolent non-Hodgkin lymphoma.

Dr van Meerten on the Role of Brexu-Cel in High-Risk MCL

February 4th 2025

Tom van Meerten, MD, PhD, discusses the role of brexucabtagene autoleucel in high-risk MCL.

Secondary Primary Cancer Prevention Strategies Following CAR T-Cell Therapy Are Underway

February 4th 2025

Optimized T-cell manufacturing is one strategy that may prevent SPCs after CAR T-cell therapy, according to Shyam A. Patel, MD, PhD, and Saurabh Dahiya, MD, FACP.

UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL

February 4th 2025

UF-Kure19, a rapidly manufactured CAR T-cell therapy, generated an 80% complete response rate in relapsed/refractory non-Hodgkin lymphoma.

TAK-007 Shows Favorable Safety, Early Efficacy Data in R/R B-Cell Non-Hodgkin Lymphoma

February 4th 2025

A phase 2 study demonstrated that TAK-007 had a favorable safety profile with early efficacy in relapsed/refractory B-cell non-Hodgkin lymphoma.

The OncFive: Top Oncology Articles for the Week of 1/26

February 1st 2025

T-DXd wins FDA approval in HER2-low and -ultralow breast cancer, 177 Lutetium edotreotide boosts PFS in GEP-NETS, and more from OncLive this week.

Dr Leslie on the Efficacy of Axi-Cel in Relapsed/Refractory MZL

January 31st 2025

Lori A. Leslie, MD, discusses efficacy data from the phase 2 ZUMA-5 trial evaluating axi-cel in relapsed/refractory marginal zone lymphoma.

Dr Patel on Second Primary Cancer Prevention Strategies After CAR T-Cell Therapy

January 31st 2025

Shyam A. Patel, MD, PhD, discusses secondary prevention strategies that may mitigate the risk of developing SPCs after receipt of CAR T-cell therapy.

Dr Dahiya on the Pathobiology of Second Primary Cancers After CAR T-Cell Therapy

January 31st 2025

Saurabh Dahiya, MD, FACP, details the pathobiology of second primary cancers following receipt of CAR T-cell therapy for hematologic malignancies.

CAR T-Cell Therapy Results in Secondary Primary Cancers in Approximately 4% of Patients

January 31st 2025

Shyam A. Patel, MD, PhD, and Saurabh Dahiya, MD, FACP, detail the pathobiology of SPCs after CAR T-cell therapy and findings from a review on the cancers.

Dr Davila on Efforts to Overcome CD19-Directed CAR T-Cell Therapy Resistance in LBCL

January 30th 2025

Marco Davila, MD, PhD, discusses emerging strategies to overcome resistance to CD19-directed CAR T-cell therapy in aggressive large B-cell lymphoma.